Moderna Inc. closed $127.61 below its 52-week high ($170.47), which the company achieved on May 24th.

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

Shares of Moderna Inc. MRNA slipped 9.07% to $41.51 Tuesday, on what proved to be an all-around grim trading session for the ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

MicroStrategy could join the Nasdaq 100, replacing Moderna. Its Bitcoin investments fuel growth while tech classification circumvents rules.

Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's ...

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines ...

Moderna's new facility will have the capacity to produce up to 100 million vaccine doses each year for respiratory diseases.